Keros Therapeutics (KROS) Superinvestor holders
11 of the superinvestors we track hold Keros Therapeutics (KROS) in their latest 13F filings, $41M in total.
Summary
The largest holder is Wilmot Harkey (Nantahala Capital Management), with $15M, 0.9% of the portfolio.
In their latest quarter: 1 opened a new position, 2 added, 8 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Wilmot Harkey Nantahala Capital Management |
Added | 1,410,419 | $15M | 0.9% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | 967,859 | $10M | 0.0% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Trimmed | 359,086 | $4M | 0.0% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Trimmed | 267,460 | $3M | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Trimmed | 246,649 | $3M | 0.0% | Q2 2026 |
| Arrowstreet Capital | Trimmed | 233,175 | $2M | 0.0% | Q2 2026 |
| Man Group Man Group plc |
Trimmed | 155,541 | $2M | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
Trimmed | 94,765 | $1M | 0.0% | Q3 2026 |
| Paul Marshall Marshall Wace |
New position | 34,600 | $370,220 | 0.0% | Q2 2026 |
| Peter Muller PDT Partners |
Trimmed | 11,405 | $122,034 | 0.0% | Q2 2026 |
| Steve Cohen Point72 Asset Management |
Trimmed | 10,393 | $111,205 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 11 |
| Q1 2026 | 14 |
| Q4 2025 | 11 |
| Q3 2025 | 11 |
| Q2 2025 | 10 |
| Q1 2025 | 12 |
| Q4 2024 | 11 |
| Q3 2024 | 13 |
Questions about Keros Therapeutics
Which superinvestors own Keros Therapeutics?
11 of the superinvestors we track hold Keros Therapeutics (KROS) in their latest 13F filings, $41M in total. Wilmot Harkey, Cliff Asness, Jim Simons, David Shaw, Two Sigma, Arrowstreet Capital.
Who is the largest superinvestor holder of KROS?
The largest holder is Wilmot Harkey (Nantahala Capital Management), with $15M, 0.9% of the portfolio.
From Keros Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.